Gustave Roussy partners with One Biosciences, a techbio company that harnesses single-cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single-nuclei transcriptomic analysis into the patient care pathway.

Gustave Roussy, Europe’s leading cancer centre, is teaming up with One Biosciences to harness the cutting-edge potential of OneMapTM, the single-cell and AI-powered solution helping to enhance precision oncology solutions. By analysing anonymised frozen samples across four cancer indications, One Biosciences will deploy OneMapTM to generate ultra-high-resolution single-cell data, unlocking the hidden functional diversity of each tumour with unparalleled precision.

Prof. Sophie Postel-Vinay, oncologist at Gustave Roussy, team leader in Inserm unit U981 at Gustave Roussy and associate professor at University College of London, comments: “I have seen firsthand how single-cell analysis can uncover mechanisms of treatment resistance in retrospective studies. I am very excited about using the OneMapTM solution in a prospective setting, fully integrated into the clinical workflow, as it could represent a major step forward in selecting the most appropriate treatment for each patient. We believe that OneMapTM's game-changing advantage is clear: deciphering tumour heterogeneity at the single-cell level, pinpointing unique cell populations, and exposing their function will empower clinicians and allow to make more informed and smarter decisions in the treatment of patients with advanced cancer.”

Leveraging advanced AI algorithms, OneMapTM will deliver individualised, actionable reports rapidly. The mission? To prove that real-time insights can seamlessly integrate into tumour molecular board reviews and ultimately patient treatment decisions

This project is the next bold step in an established partnership between One Biosciences and Gustave Roussy, leveraging single-cell analysis to predict treatment response. It follows an initial feasibility study on retrospective samples, which successfully demonstrated both effective sample processing and the delivery of individualised reports.

Dr Céline Vallot, co-founder and CSO of One Biosciences, said: "This project is a testament to the transformative power of One Biosciences’ end-to-end innovation - from pioneering laboratory workflows that unlock high-fidelity single-cell data to our AI-driven bioinformatics platform, OneMapTM, which automates analysis and delivers clinically actionable insights directly to physicians. Beyond proving feasibility, its success has the potential to revolutionise standard-of-care diagnostics, paving the way for large-scale adoption. We are excited to reveal the results and anticipate sharing this work with the oncology community.”